|
|
 |
|
Viewing report
|
|
|
|
Hyperparathyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017
GlobalData, Dec 2011, Pages: 59
Hyperparathyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, “Hyperparathyroidism Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global hyperparathyroidism therapeutics market. The report identifies the key trends shaping and driving the global hyperparathyroidism therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global hyperparathyroidism therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GlobalData estimated that the global hyperparathyroidism therapeutics market valued $2 billion in 2010, after increasing at a Compound Annual Growth Rate (CAGR) of 17.9% during 2005–2010. It is forecast to grow at a CAGR of 7.6% for the next seven years to reach $3.4 billion by 2017. The major breakthrough in the hyperparathyroidism market was the approval of Amgen’s cinacalcet under the brand names of Sensipar in the US by the US Food and Drug Administration (FDA) and as Mimpara in Europe by European Medicines Agency (EMEA) in October, 2004. In Japan cinacalcet is marketed by Kyowa Hakko Kirin under the brand name of Regpara. This growth forecast is primarily based on the increasing prevalence of the disease.
Scope
The report provides information on the key drivers and challenges of the hyperparathyroidism therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) hyperparathyroidism therapeutics market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes such as vitamin-D receptor agonists; CYP24 inhibition coupled with vitamin-D receptor agonist; and calcium and phosphorus level regulator.
- Analysis of the current and future competition in the seven key countries hyperparathyroidism therapeutics market. Key market players covered are Cytochroma Inc., KAI Pharmaceuticals, Abbott Laboratories and LEO Pharma.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the hyperparathyroidism therapeutics market.
- Analysis of key recent licensing and partnership agreements in hyperparathyroidism therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global hyperparathyroidism therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global hyperparathyroidism therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global hyperparathyroidism therapeutics market landscape? – Identify, understand and capitalize.
Keywords
Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials
|
|
|
|
